Straits Times Index
3,074.26 -12.98 (-0.42%) S&P 500
4,584.79 +35.45 (+0.78%) Dow
36,128.61 +74.18 (+0.21%) Nasdaq
14,339.08 +192.37 (+1.36%) Bitcoin USD
43,365.41 -633.23 (-1.44%) CMC Crypto 200
893.89 +1.17 (+0.13%)
Molecular Templates, Inc. (MTEM)
| Previous close | 5.15 |
| Open | 4.90 |
| Bid | 4.76 x 1000 |
| Ask | 5.17 x 800 |
| Day's range | 4.75 - 5.17 |
| 52-week range | 4.56 - 9.60 |
| Volume | |
| Avg. volume | 8,195 |
| Market cap | 27.785M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.92 |
| Earnings date | 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.50 |
GlobeNewswireMolecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
MT-6402 Dose Escalation (Part A) Head & Neck Patients (N=8) AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the th
GlobeNewswireMolecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors. The Phase 1 study is a multi-center open-lab
- GlobeNewswire
Molecular Templates to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences: UBS Biopharma Conference 2023 Format: One-on-One
